Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check7 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check14 days agoChange DetectedPublications section now states that publications are automatically filled from PubMed and displays revision: v3.3.1. The previous PubMed-origin wording and the older revision (v3.2.0) have been removed.SummaryDifference0.1%

- Check21 days agoChange DetectedThe site-wide government funding status notice has been removed. This administrative change does not affect the study details, eligibility criteria, or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedResults for NCT03222856 have been posted, including efficacy and safety outcomes. The study record now shows updated completion and enrollment dates.SummaryDifference0.4%

- Check64 days agoChange DetectedUpgrade to v3.2.0 with a prominent operating-status notice and links; v3.1.0 is removed.SummaryDifference2%

- Check71 days agoChange DetectedUpdate versioning from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.